The next focusIR Investor Webinar takes place tomorrow with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIq-ai Ltd Regulatory News (IQAI)

Share Price Information for Iq-ai Ltd (IQAI)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.55
Bid: 1.50
Ask: 1.60
Change: -0.10 (-6.06%)
Spread: 0.10 (6.667%)
Open: 1.65
High: 1.65
Low: 1.55
Prev. Close: 1.65
IQAI Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Placing, Notice of AGM and GM

16 Jul 2018 07:00

RNS Number : 6600U
Flying Brands Limited
16 July 2018
 

FLYING BRANDS LIMITED

("Flying Brands" or the "Company")

 

Placing, Notice of Annual General Meeting and General Meeting

 

This announcement contains information which prior to its disclosure was inside information for the purposes of the Market Abuse Regulation.

 

The Company is pleased to announce that Peterhouse Capital has raised £500,000 (before expenses) pursuant to a conditional placing (the "Placing") of 20,000,000 Ordinary Shares (the "Placing Shares") at a price of 2.5 pence per Placing Share.

 

The monies raised from the Placing will be used, inter-alia, for:

· Obtaining FDA clearance for StoneChecker Software;

· To design and manufacture a commercial version of the cloud-based interface for StoneChecker software;

· Commercial sales of StoneChecker Software in the UK; and

· Launch both StoneChecker Software and Imaging Biometrics' products commercially in the US, India and China.

 

The Placing is subject to shareholder approval at the forthcoming General Meeting and admission to the standard segment of the Official List ("Admission"). Accordingly, the Company also announces the publication of a Circular including notice of an annual general meeting (the "AGM") and a general meeting (the "GM") to be held at 3 p.m. and 3:15 p.m respectively on 31 July 2018 at Anglo Saxon Trust Limited, Forum 4, Grenville Street, St Helier, Jersey, Channel Islands JE4 8TQ.

 

At the GM, shareholders are also being requested to approve inter-alia (1) the issue of 6,200,000 Ordinary Shares to the sellers of Imaging Biometrics LLC ("IB") to satisfy the remaining consideration shares due under the Share Purchase Agreement between IB and the Company ("Further Consideration Shares"); (2) the conversion of £195,050 11 March 2015 convertible loan notes into 21,787,061 Ordinary Shares (the "Convertible Shares"). If the resolutions are approved at the GM and subject to Admission, Trevor Brown will be directly and indirectly (through Free Association Books) interested in 36,083,025 shares which is 29.98% of the enlarged share capital.

 

In addition, the Company has posted to shareholders a draft Prospectus (subject to UKLA and Jersey FCA approval) to enable the issue of the Placing Shares, the Further Consideration Shares and the Convertible Shares.

 

The resolutions to be proposed at the AGM are:

 

Ordinary business

 

1. To receive, approve and adopt the Company's audited financial statements, together with the reports of the directors and the auditor, for the year ended 31 December 2017.

 

2. To re-elect as a director of the Company Vinod Kaushal (who retires as a director in accordance with the Articles of Association of the Company) and who, being eligible, offers himself for re-election.

 

3. To appoint Welbeck Associates as auditors of the Company to hold office from the conclusion of the meeting until the conclusion of the next annual general meeting of the Company and to authorise the directors to fix their remuneration.

 

Special business

4. That the Company be generally and unconditionally authorised pursuant to Article 57(2) of the Companies (Jersey) Law 1991 (as amended) to make one or more market purchases of its own shares, such purchases to be of ordinary shares of £0.01 each in the capital of the Company (Ordinary Shares) on the London Stock Exchange, provided that:

a. no purchase of Ordinary Shares may be effected without the affirmative prior sanction by a majority of not less than three fourths of the holders (as to nominal value) of the Company's issued convertible loan notes; and

b. subject to paragraph (a) above:

i. the maximum number of Ordinary Shares hereby authorised to be purchased shall be 18,051,974 Ordinary Shares, being approximately 15% of the issued share capital of the Company immediately following Re-admission;

ii. the minimum price which may be paid for any such Ordinary Shares shall be £0.01 per Ordinary Share (exclusive of expenses);

iii. the maximum price (exclusive of expenses) which may be paid for an Ordinary Share shall not be more than the higher of: (i) an amount equal to 105% of the average of the middle market quotations for an Ordinary Share (as derived from the London Stock Exchange Daily Official List) for the five business days immediately preceding the date on which that Ordinary Share is contracted to be purchased and (ii) the amount stipulated by the Regulatory Technical Standard adopted by the European Commission pursuant to Article 5(6) of the Markey Abuse Regulation (EU) No. 596/2014unless otherwise varied renewed or revoked the authority hereby conferred shall expire at the conclusion of the next annual general meeting of the Company; and

iv. prior to expiry of the authority hereby conferred the Company may enter into a contract or contracts for the purchase of Ordinary Shares which may be executed in whole or part after such expiry and may purchase Ordinary Shares pursuant to such contract or contracts as if the authority hereby conferred had not so expired.

 

The resolutions to be proposed at the GM are:

 

Special resolution

 

1. THAT the Company's authorised share capital be increased from £800,000 to £1,500,000 by replacing paragraph 6 of the memorandum of association of the Company with the following provision:

 

"The share capital of the Company is £1,500,000 divided into 150,000,000 Ordinary Shares of £0.01 each"

 

Ordinary resolution

2. THAT, in accordance with Article 4.1 of the Articles, the directors of the Company be generally and unconditionally authorised to allot, or grant rights to subscribe for or covert any security into, shares in the capital of the Company up to an aggregate nominal amount of £479,870.61 (comprising the Placing Shares, Further Consideration Shares and Convertible Shares) and up to an aggregate nominal amount of £240,692.98 (comprising additional headroom of 20 per cent).

 

Special resolution

3. THAT any pre-emption rights that would otherwise arise by virtue of Article 4.6 of the Articles or any other provision of the Articles or otherwise in relation to the allotment of ordinary shares or the grant of rights by the directors pursuant to the authority contained in Resolution 2 above are hereby disapplied, provided that this authority shall, unless renewed, varied or revoked by the Company, expire on the date falling five years after the date of these Resolutions save that the Company may, before such expiry, make an offer or agreement which would or might require shares to be allotted or rights to be granted and the directors may allot shares or grant rights in pursuance of such offer or agreement notwithstanding that the authority conferred by this resolution has expired.

 

The following documents have been published and will be available on the Company's website www.flyingbrands.com and from the Company's registered address at P.O Box 264, Forum 4, Grenville Street, St Helier, Jersey, Channel Islands JE4 8TQ:

 

1. the draft Prospectus, which is subject to UKLA and Jersey FCA approval;

2. the Circular for the Company (including notice of the AGM and GM);

3. the Company's audited accounts for the year ended 31 December 2017.

 

The draft Prospectus, the Circular and the Company's audited accounts have been posted to shareholders.

 

The Directors of the Company accept responsibility for the contents of this announcement.

 

**ENDS**

 

For further information please contact:

 

Flying Brands Limited

Qu Li/Trevor Brown/Vinod Kaushal

Tel: 020 7469 0930

 

Peterhouse Capital Limited (Financial Advisor and Broker)

Lucy Williams/Heena Karani

Tel: 020 7220 9797

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
 
END
 
 
STRBLGDRRXBBGIX
Date   Source Headline
10th May 20248:15 amRNSRare Pediatric Disease Designation Granted to GaM
2nd May 202412:47 pmRNSIB Announces Expanded Access Program for GaM
29th Apr 20243:26 pmRNSPublication of Annual Report
5th Mar 20247:00 amRNSGrant of Options
1st Mar 20248:22 amRNSHolding(s) in Company
1st Mar 20248:20 amRNSHolding(s) in Company
26th Feb 20247:00 amRNSResult of Broker Option and Total Voting Rights
22nd Feb 20247:00 amRNSPlacing and Broker Option
9th Feb 202412:49 pmRNSFDA Application Update
2nd Feb 20248:39 amRNSIB awarded a $100,000 grant
22nd Jan 202410:05 amRNSHolding(s) in Company
15th Jan 20247:01 amRNSDirector Dealings and Conversion of CLNs
15th Jan 20247:00 amRNSHolding(s) in Company
10th Jan 20247:00 amRNSIB Launching an Expanded Access Program for GaM
19th Dec 20232:29 pmRNSImaging Biometrics granted FDA “Fast-Track”
5th Dec 202310:58 amRNSIQ-AI Announces Positive Interim Phase 1 Results
20th Nov 20231:42 pmRNSHolding(s) in Company
9th Nov 202311:38 amRNSDirector Dealing and Conversion of CLNs
8th Nov 202310:59 amRNSApplication for Pediatric Rare Disease Designation
6th Nov 20231:02 pmRNSHolding(s) in Company
18th Oct 20232:29 pmRNSUpdate Regarding Imaging Biometrics LLC
13th Oct 20238:55 amRNSIB Letter to Shareholders
9th Oct 20237:00 amRNSOrphan Drug Status to GaM and Total Voting Rights
3rd Oct 202311:30 amRNSHolding(s) in Company
19th Sep 20232:32 pmRNSIQ-AI shares cease trading on the OTCQB
8th Sep 20237:00 amRNSReduced Gadolinium Approach Validated'
18th Aug 202312:06 pmRNSUpdate on Collaboration Agreement with Mayo Clinic
18th Aug 202311:20 amRNSIB & GE HealthCare Enter into Commercial Agreement
17th Aug 20237:00 amRNSHalf-year Report
19th Jul 20237:00 amRNSImaging Biometrics Installs IB Nimble™ For MCW
13th Jul 20237:00 amRNSOrphan Drug Designation for GaM in Pediatric GBM
27th Jun 20237:00 amRNSStudies Show GaM Inhibits Pediatric Tumor Growth
23rd May 202311:02 amRNSResult of AGM
23rd May 20237:00 amRNSAGM Statement
3rd May 20234:14 pmRNSNotice of AGM
26th Apr 20237:00 amRNSFinal Results
28th Feb 20233:52 pmRNSOrphan Drug Designation Status
13th Jan 20232:05 pmRNSSecond Price Monitoring Extn
13th Jan 20232:00 pmRNSPrice Monitoring Extension
13th Jan 202311:05 amRNSSecond Price Monitoring Extn
13th Jan 202311:00 amRNSPrice Monitoring Extension
10th Jan 20237:00 amRNSLetter to Shareholders
2nd Dec 202211:11 amRNSHolding in Company
25th Oct 202211:00 amRNSPrice Monitoring Extension
30th Sep 20227:00 amRNSLetter to Shareholders
26th Sep 20227:00 amRNSIssue of Warrants to Employees
16th Aug 20224:40 pmRNSSecond Price Monitoring Extn
16th Aug 20224:35 pmRNSPrice Monitoring Extension
16th Aug 20229:28 amRNSHalf-year Report
3rd Aug 20221:01 pmRNSTR1 - Notification of Major Holdings

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.